| Similar Articles |
|---|
 |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances?   |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
The Motley Fool
February 16, 2007
Brian Lawler |
Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
April 2, 2007
Brian Lawler |
FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note. |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
The Motley Fool
August 19, 2004
Charly Travers |
1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL. |
The Motley Fool
November 9, 2007
Brian Lawler |
Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher. |
The Motley Fool
February 14, 2008
Brian Lawler |
Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
The Motley Fool
October 22, 2009
Robert Steyer |
Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats. |
The Motley Fool
June 27, 2006
Brian Lawler |
Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity. |
The Motley Fool
August 3, 2007
Brian Lawler |
Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look. |
The Motley Fool
October 18, 2005
Stephen D. Simpson |
Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note. |
The Motley Fool
October 18, 2006
Brian Lawler |
Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees. |
BusinessWeek
November 1, 2004
Amy Barrett |
This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight. |
The Motley Fool
February 17, 2006
Brian Gorman |
Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious. |
The Motley Fool
September 26, 2006
Brian Lawler |
A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note. |
The Motley Fool
November 4, 2004
Charly Travers |
Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important. |
The Motley Fool
January 18, 2012
Sean Williams |
This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount. |
The Motley Fool
April 16, 2008
Brian Orelli |
Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development. |
The Motley Fool
January 16, 2008
Brian Orelli |
Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again. |
The Motley Fool
July 6, 2006
Brian Lawler |
Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement. |
The Motley Fool
August 27, 2007
Brian Lawler |
Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
January 10, 2007
Rich Duprey |
Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest. |
The Motley Fool
November 6, 2006
Brian Lawler |
No Worries About Cephalon This solid biopharma ups its yearly guidance -- for the fourth time. Investors, take note. |
The Motley Fool
May 18, 2011
Sean Williams |
10 Mid Caps to Rule Them All The future of Jazz Pharmaceuticals' narcolepsy drug is so bright you may actually sleep better at night. |
The Motley Fool
July 18, 2006
Stephen D. Simpson |
Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch. |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
The Motley Fool
April 1, 2008
Brian Lawler |
Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere. |
Chemistry World
June 1, 2015
Phillip Broadwith |
Teva fined $1.2bn in pay-for-delay case Israeli firm Teva has reached a settlement with the US Federal Trade Commission over allegations of cutting illegal deals with generic drugmakers to stifle competition for sleep disorder drug Provigil (modafinil). |
BusinessWeek
April 24, 2006
Arlene Weintraub |
Eyes Wide Open Cephalon's careful marketing of its narcolepsy drug could serve as a manual for turning new ideas into hit products. |
The Motley Fool
May 2, 2011
Arundhati Parmar |
Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies. |
The Motley Fool
August 13, 2004
Rich Duprey |
Cima's Breakup Mess The pharmaceutical company seeks to recoup its fees plus damages from a former suitor. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
The Motley Fool
April 27, 2007
Brian Lawler |
Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma. |
The Motley Fool
March 12, 2009
Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another. |
The Motley Fool
December 31, 2007
Brian Lawler |
Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008. |
The Motley Fool
March 24, 2006
Brian Gorman |
Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity. |
The Motley Fool
September 14, 2007
Brian Lawler |
"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note. |
The Motley Fool
June 27, 2005
Brian Gorman |
Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
April 12, 2004
Brian Gorman |
Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors. |
The Motley Fool
March 30, 2010
Brian Orelli |
FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag. |
The Motley Fool
January 21, 2004
Alyce Lomax |
Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit. |
